Faculty of Medicine, Dentistry and Health Sciences Department of Surgery Austin Health

Regulatory Peptides Research Group

Regulatory Peptides Research Group Photo

The Regulatory Peptides Research Group is headed by Prof Arthur Shulkes and Assoc Prof Graham Baldwin which focuses on the mechanisms by which peptide growth factors stimulate the growth of the normal gastrointestinal mucosa and the development of gastrointestinal and other cancers. At present we are concentrating on two structurally un-related growth factors, gastrin and gastrin-releasing peptide. Our long term goal is to design and test new therapies for colorectal carcinoma (CRC). As the same growth factors are probably involved in other cancers we are also investigating prostate and renal cancers.
The gastrin field has been revolutionised in the past decade by the discovery that non-amidated gastrins (NAGs) have a completely different spectrum of biological activities from mature amidated gastrin (1). Studies from several laboratories including our own have shown that, as well as stimulating the proliferation and migration of a variety of cell lines in vitro (2), NAGs promote proliferation of the colonic mucosa, and accelerate CRC development in vivo. Clinical studies have shown that CRC produce NAGs, that circulating concentrations of NAGs are increased in patients with CRC, and that a circulating gastrin concentration above normal was associated with a 3.9-fold greater risk of developing CRC.Despite the potential importance of these discoveries it is not clear which are the bioactive NAGs, the structure of the receptor(s) responsible remains undefined, and no selective antagonists are available.

We recently demonstrated that gastrins selectively bind two Fe3+ ions with high affinity, and that binding of Fe3+ ions is essential for the biological activity of NAGs. These observations stimulated a reappraisal of the role of gastrins in metal ion homeostasis, which led to our unexpected observation that circulating gastrin is increased in animals and humans with iron overload (5). We are currently investigating whether alteration of gastrin expression results in reciprocal changes in iron homeostasis.

Gastrin-releasing peptide (GRP) was initially discovered in the stomach, and named for its potent stimulation of gastrin release (3). However the widespread distribution of GRP, with significant amounts present in the central nervous system and throughout the entire gastrointestinal tract, suggests more general actions. In particular GRP has been recognised as the prototypical autocrine growth factor, based on the detection of GRP and its cognate receptor in small cell lung carcinoma (SCLC). GRP is also a potent mitogen for several other types of carcinomas including colorectal, pancreas, prostate, and breast. Although it has been assumed that bioactive GRP peptides are derived exclusively from residues 1-27 of the GRP precursor proGRP, peptides derived from the C-terminus of proGRP are present in normal and tumour tissues. We have expressed several C-terminal fragments of proGRP in bacteria, and are now investigating their biological activities in vitro (6), and in animal models of CRC.  We are also investigating the role of the GRP peptides in prostate and renal carcinomas.

The laboratory is funded through multiple NHMRC Project Grants, through the Austin Hospital Medical Research Foundation, and through a NIH (USA) Project Grant “The Biology of Gastrin-Ferric Ion Complexes” held by Assoc. Prof. Graham Baldwin with Prof. Shulkes, Assoc. Prof. Greg Anderson (Queensland Institute for Medical Research), Prof. Ray Norton (the Walter and Eliza Hall Institute) and Prof. Ted Baker (University of Auckland).

Research Staff

top of page

Higher Degree Students

top of page

Graduating Students

top of page

Research Higher Degree and Undergraduate Degree graduating students are listed on the graduating students page.

Publications

top of page

Research Publications from 2003 onwards are available on the Research Publications page.

Funding

top of page

Details of research funding from 2003 onwards is available from the Research Funding page.

top of page